Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vortioxetine ODT vs Trintellix in Healthy Adults
NCT05417087Phase 1Completed
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Seasons Biotechnology (Taizhou) Co., Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Infinity. Started Jun 2022; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05417087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417087.